Genesdifferentially expressed in AML MPs are enriched for potential p53 target genes. (A) Venn diagrams illustrating the overlap among DE genes in AML MPs, p53 target genes involved in DNA damage response (“targets”), and the genes with p53 binding peaks close to their loci (“peaks”). “Targets” and “peaks” have been described previously.⁴⁵  (B) Heat map displaying statistically significant (FDR <0.001), top 100 up- and downregulated genes in AML MPs (based on fold change). Genes in green are p53 target genes involved in DNA damage response, whereas genes in orange are genes with p53 binding peaks close to their loci but not regulated by p53 in DNA damage response. (C) Genomic views of p53 binding peaks at 4 representative gene loci. (D-E) Validation of differentially expressed genes in AML MPs vs control MPs using quantitative reverse transcriptase polymerase chain reaction (qRT-PCR). Total RNAs were extracted from sorted control and AML MPs using RNEasy Mini Kit (Qiagen). Complementary DNAs (cDNAs) were synthesized using iScript cDNA Synthesis Kit (Bio-Rad). qRT-PCR was performed by using PrimeTime qPCR Assay (ITD; Integrated DNA Technologies) and Maxima Probe qPCR Master Mix (Thermo Scientific) on a CFX96 Real-Time System (Bio-Rad) according to the manufacturer’s instructions. Quantification results of (D) 4 up- and (E) 4 downregulated genes in AML MPs vs control MPs are shown here. Data are presented as mean ± SD. *P < .05; **P < .01; ***P < .001. Log₂FC, fold change expressed as 2-based log units.